Penny Stock Soars on FDA News

The company is appealing an early August FDA decision

by Karee Venema

Published on Nov 12, 2018 at 9:33 AM

The shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) are trading up 5.6% at $1.21, after the biopharm said it is appealing the Food and Drug Administration's (FDA) decision on its pain drug, Remoxy. Back in August, the regulatory agency failed to approve Remoxy, after an advisory panel voted overwhelmingly against the treatment, citing potential abuse risks. A meeting date between the two has been set for Thursday, Jan. 31, 2019.

It's been a rough stretch for PTIE stock since that late-June FDA advisory panel ruling. Since gapping more than 71% lower on June 27, the equity has been stuck churning in penny-stock territory, with the $2.80 region -- home to its post bear-gap highs -- serving as stiff resistance.

Short sellers have been in the driver's seat throughout these technical troubles. Short interest has nearly quadrupled since mid-June. Plus, the 2.5 million PTIE shares currently sold short represents nearly 17% of the stock's available float.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.
Options Traders Blast SDC amd GOOS Stocks
SDC and GOOS options volume has ramped up today
Alibaba Stock Drops Amid Hong Kong IPO Buzz
Alibaba expects to raise up to $15 billion in its Hong Kong IPO
IRA/401K Investment Guide: 2019 Stock Market Crash
Use gold to protect any IRA, 401(k), or retirement account from a looming financial crisis.